MARKET

ONCO

ONCO

Onconetix
NASDAQ
1.790
-0.050
-2.72%
Opening 13:24 12/19 EST
OPEN
1.810
PREV CLOSE
1.840
HIGH
1.880
LOW
1.766
VOLUME
30.10K
TURNOVER
--
52 WEEK HIGH
179.35
52 WEEK LOW
1.766
MARKET CAP
2.79M
P/E (TTM)
-0.0051
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ONCO last week (1208-1212)?
Weekly Report · 4d ago
Onconetix Inc. Files Initial Statement of Beneficial Ownership for Director Sarah Romano
Reuters · 6d ago
Onconetix Approves CEO Bonus and Stockholder Proposals
TipRanks · 12/10 22:29
Onconetix Inc. Held Annual Shareholder Meeting
Reuters · 12/10 22:01
Onconetix Amends License Agreement with Labcorp
TipRanks · 12/10 14:47
Proteomedix AG Launches PRIME Study Under Onconetix Inc
Reuters · 12/10 14:28
Weekly Report: what happened at ONCO last week (1201-1205)?
Weekly Report · 12/08 10:19
Weekly Report: what happened at ONCO last week (1124-1128)?
Weekly Report · 12/01 10:15
More
About ONCO
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.

Webull offers Onconetix Inc stock information, including NASDAQ: ONCO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ONCO stock methods without spending real money on the virtual paper trading platform.